Chemical Compound Review:
AC1O535C 1-(9H-carbazol-3-yloxy)-3-[2- (2...
Synonyms:
Macdonald,
Keogh,
Aboyoun,
Lund,
Amor,
McCaffrey,
Ohno,
Saito,
Hanioka,
Jinno,
Saeki,
Ando,
Ozawa,
Sawada,
Watanabe,
Kakihana,
Ohtsuka,
Sugishita,
Di Lenarda,
Sabbadini,
Salvatore,
Sinagra,
Mestroni,
Pinamonti,
Gregori,
Ciani,
Muzzi,
Klugmann,
Camerini,
Sofuoglu,
Mouratidis,
Yoo,
Kosten,
McMurray,
Køber,
Robertson,
Dargie,
Colucci,
Lopez-Sendon,
Remme,
Sharpe,
Ford,
Yancy,
Fowler,
Colucci,
Gilbert,
Bristow,
Cohn,
Lukas,
Young,
Packer,
Dargie,
Fowler,
Vera-Llonch,
Oster,
Bristow,
Cohn,
Colucci,
Gilbert,
Lukas,
Lacey,
Richner,
Young,
Packer,
Tarantini,
Cioffi,
Opasich,
Di Lenarda,
Pulignano,
Del Sindaco,
De Feo,
Stefenelli,
Russo,
Catania,
- Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial. Dargie, H.J. Lancet (2001)
- Metabolic and cardiovascular effects of carvedilol and atenolol in non-insulin-dependent diabetes mellitus and hypertension. A randomized, controlled trial. Giugliano, D., Acampora, R., Marfella, R., De Rosa, N., Ziccardi, P., Ragone, R., De Angelis, L., D'Onofrio, F. Ann. Intern. Med. (1997)
- Double-blind, placebo-controlled study of the long-term efficacy of carvedilol in patients with severe chronic heart failure. Krum, H., Sackner-Bernstein, J.D., Goldsmith, R.L., Kukin, M.L., Schwartz, B., Penn, J., Medina, N., Yushak, M., Horn, E., Katz, S.D. Circulation (1995)
- Possible involvement of stress-activated protein kinase signaling pathway and Fas receptor expression in prevention of ischemia/reperfusion-induced cardiomyocyte apoptosis by carvedilol. Yue, T.L., Ma, X.L., Wang, X., Romanic, A.M., Liu, G.L., Louden, C., Gu, J.L., Kumar, S., Poste, G., Ruffolo, R.R., Feuerstein, G.Z. Circ. Res. (1998)
- Influence of pretreatment systolic blood pressure on the effect of carvedilol in patients with severe chronic heart failure: the Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) study. Rouleau, J.L., Roecker, E.B., Tendera, M., Mohacsi, P., Krum, H., Katus, H.A., Fowler, M.B., Coats, A.J., Castaigne, A., Scherhag, A., Holcslaw, T.L., Packer, M. J. Am. Coll. Cardiol. (2004)
- Nightmares and panic disorder associated with carvedilol overdose. Maebara, C., Ohtani, H., Sugahara, H., Mine, K., Kubo, C., Sawada, Y. The Annals of pharmacotherapy. (2002)
- Adrenergic blocker carvedilol attenuates the cardiovascular and aversive effects of nicotine in abstinent smokers. Sofuoglu, M., Mouratidis, M., Yoo, S., Kosten, T. Behavioural pharmacology (2006)
- General pharmacological profiles of the new beta-adrenoceptor antagonist carvedilol. Hirohashi, M., Takasuna, K., Tamura, K., Yamaguchi, K., Maekawa, K., Yamada, S., Iwasaki, S., Yoshida, M., Nomura, M., Taguchi, K. Arzneimittel-Forschung. (1990)
- Pre-discharge initiation of beta-blocker therapy in elderly patients hospitalized for acute decompensation of chronic heart failure: an effective strategy for the implementation of beta-blockade in heart failure. Tarantini, L., Cioffi, G., Opasich, C., Di Lenarda, A., Pulignano, G., Del Sindaco, D., De Feo, S., Stefenelli, C., Russo, P., Catania, G. Italian heart journal : official journal of the Italian Federation of Cardiology. (2004)
- Race and the response to adrenergic blockade with carvedilol in patients with chronic heart failure. Yancy, C.W., Fowler, M.B., Colucci, W.S., Gilbert, E.M., Bristow, M.R., Cohn, J.N., Lukas, M.A., Young, S.T., Packer, M. N. Engl. J. Med. (2001)
- The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group. Packer, M., Bristow, M.R., Cohn, J.N., Colucci, W.S., Fowler, M.B., Gilbert, E.M., Shusterman, N.H. N. Engl. J. Med. (1996)
- Beta 1-adrenergic receptor polymorphisms confer differential function and predisposition to heart failure. Mialet Perez, J., Rathz, D.A., Petrashevskaya, N.N., Hahn, H.S., Wagoner, L.E., Schwartz, A., Dorn, G.W., Liggett, S.B. Nat. Med. (2003)
- beta-Blocker therapy in heart failure: scientific review. Foody, J.M., Farrell, M.H., Krumholz, H.M. JAMA (2002)
- Real-time optical recording of beta(1)-adrenergic receptor activation reveals supersensitivity of the Arg389 variant to carvedilol. Rochais, F., Vilardaga, J.P., Nikolaev, V.O., B??nemann, M., Lohse, M.J., Engelhardt, S. J. Clin. Invest. (2007)
- Randomized comparison of long-term carvedilol and propranolol administration in the treatment of portal hypertension in cirrhosis. Bañares, R., Moitinho, E., Matilla, A., García-Pagán, J.C., Lampreave, J.L., Piera, C., Abraldes, J.G., De Diego, A., Albillos, A., Bosch, J. Hepatology (2002)
- Long-term effects of carvedilol in idiopathic dilated cardiomyopathy with persistent left ventricular dysfunction despite chronic metoprolol. The Heart-Muscle Disease Study Group. Di Lenarda, A., Sabbadini, G., Salvatore, L., Sinagra, G., Mestroni, L., Pinamonti, B., Gregori, D., Ciani, F., Muzzi, A., Klugmann, S., Camerini, F. J. Am. Coll. Cardiol. (1999)
- Carvedilol alone or in combination with digoxin for the management of atrial fibrillation in patients with heart failure? Khand, A.U., Rankin, A.C., Martin, W., Taylor, J., Gemmell, I., Cleland, J.G. J. Am. Coll. Cardiol. (2003)
- Effect of carvedilol in comparison with metoprolol on myocardial collagen postinfarction. Wei, S., Chow, L.T., Sanderson, J.E. J. Am. Coll. Cardiol. (2000)
- Antiarrhythmic effect of carvedilol after acute myocardial infarction: results of the Carvedilol Post-Infarct Survival Control in Left Ventricular Dysfunction (CAPRICORN) trial. McMurray, J., Køber, L., Robertson, M., Dargie, H., Colucci, W., Lopez-Sendon, J., Remme, W., Sharpe, D.N., Ford, I. J. Am. Coll. Cardiol. (2005)
- Beneficial effects of intravenous and oral carvedilol treatment in acute myocardial infarction. A placebo-controlled, randomized trial. Basu, S., Senior, R., Raval, U., van der Does, R., Bruckner, T., Lahiri, A. Circulation (1997)
- Carvedilol, a cardiovascular drug, prevents vascular smooth muscle cell proliferation, migration, and neointimal formation following vascular injury. Ohlstein, E.H., Douglas, S.A., Sung, C.P., Yue, T.L., Louden, C., Arleth, A., Poste, G., Ruffolo, R.R., Feuerstein, G.Z. Proc. Natl. Acad. Sci. U.S.A. (1993)
- Congestive heart failure induces endothelial cell apoptosis: protective role of carvedilol. Rössig, L., Haendeler, J., Mallat, Z., Hugel, B., Freyssinet, J.M., Tedgui, A., Dimmeler, S., Zeiher, A.M. J. Am. Coll. Cardiol. (2000)
- Comparative hemodynamic, left ventricular functional, and antiadrenergic effects of chronic treatment with metoprolol versus carvedilol in the failing heart. Gilbert, E.M., Abraham, W.T., Olsen, S., Hattler, B., White, M., Mealy, P., Larrabee, P., Bristow, M.R. Circulation (1996)
- Nonselective beta-adrenergic blockade with carvedilol does not hinder the benefits of exercise training in patients with congestive heart failure. Demopoulos, L., Yeh, M., Gentilucci, M., Testa, M., Bijou, R., Katz, S.D., Mancini, D., Jones, M., LeJemtel, T.H. Circulation (1997)
- Plasma N-terminal pro-brain natriuretic peptide and adrenomedullin: prognostic utility and prediction of benefit from carvedilol in chronic ischemic left ventricular dysfunction. Australia-New Zealand Heart Failure Group. Richards, A.M., Doughty, R., Nicholls, M.G., MacMahon, S., Sharpe, N., Murphy, J., Espiner, E.A., Frampton, C., Yandle, T.G. J. Am. Coll. Cardiol. (2001)
- Influence of carvedilol on hospitalizations in heart failure: incidence, resource utilization and costs. U.S. Carvedilol Heart Failure Study Group. Fowler, M.B., Vera-Llonch, M., Oster, G., Bristow, M.R., Cohn, J.N., Colucci, W.S., Gilbert, E.M., Lukas, M.A., Lacey, M.J., Richner, R., Young, S.T., Packer, M. J. Am. Coll. Cardiol. (2001)
- Preventive effects of carvedilol on nitrate tolerance--a randomized, double-blind, placebo-controlled comparative study between carvedilol and arotinolol. Watanabe, H., Kakihana, M., Ohtsuka, S., Sugishita, Y. J. Am. Coll. Cardiol. (1998)
- CYP2D6 genotype and induction of intestinal drug transporters by rifampin predict presystemic clearance of carvedilol in healthy subjects. Giessmann, T., Modess, C., Hecker, U., Zschiesche, M., Dazert, P., Kunert-Keil, C., Warzok, R., Engel, G., Weitschies, W., Cascorbi, I., Kroemer, H.K., Siegmund, W. Clin. Pharmacol. Ther. (2004)
- Involvement of human hepatic UGT1A1, UGT2B4, and UGT2B7 in the glucuronidation of carvedilol. Ohno, A., Saito, Y., Hanioka, N., Jinno, H., Saeki, M., Ando, M., Ozawa, S., Sawada, J. Drug Metab. Dispos. (2004)
- In vitro identification of the human cytochrome P450 enzymes involved in the metabolism of R(+)- and S(-)-carvedilol. Oldham, H.G., Clarke, S.E. Drug Metab. Dispos. (1997)
- Double-blind, placebo-controlled study of the effects of carvedilol in patients with moderate to severe heart failure. The PRECISE Trial. Prospective Randomized Evaluation of Carvedilol on Symptoms and Exercise. Packer, M., Colucci, W.S., Sackner-Bernstein, J.D., Liang, C.S., Goldscher, D.A., Freeman, I., Kukin, M.L., Kinhal, V., Udelson, J.E., Klapholz, M., Gottlieb, S.S., Pearle, D., Cody, R.J., Gregory, J.J., Kantrowitz, N.E., LeJemtel, T.H., Young, S.T., Lukas, M.A., Shusterman, N.H. Circulation (1996)
- Carvedilol increases the production of interleukin-12 and interferon-gamma and improves the survival of mice infected with the encephalomyocarditis virus. Nishio, R., Shioi, T., Sasayama, S., Matsumori, A. J. Am. Coll. Cardiol. (2003)
- Tolerability and efficacy of carvedilol in patients with New York Heart Association class IV heart failure. Macdonald, P.S., Keogh, A.M., Aboyoun, C.L., Lund, M., Amor, R., McCaffrey, D.J. J. Am. Coll. Cardiol. (1999)